Prime Medicine, Inc. (PRME)
PRME moved a median of +0.00% 30 minutes after news, and -1.24% by the close. How PRME actually reacts to news — the realized, point-in-time move the market made, measured across 236 labeled events over the last three years with zero look-ahead.
PRME’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.19% | 47% | 236 |
| 30-min | +0.00% | 50% | 236 |
| 60-min | +0.16% | 50% | 236 |
| to close | -1.24% | 45% | 234 |
| Middle 50% of PRME reactions | -1.95% to +3.56% |
|---|---|
| Median reaction (30-min) | +0.00% |
| Measured reactions | 236 |
Half of all Prime Medicine, Inc. news events land between -1.95% and +3.56% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How PRME reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 25 | 0.00% | 48% | -0.27% |
| Analyst downgrades | 14 | -5.04% | 29% | -6.91% |
| Coverage initiations | 32 | -1.75% | 25% | -0.40% |
| Rating reiterations | 44 | -0.12% | 43% | -3.12% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how PRME ranks against every other measured name →
That’s how PRME usually reacts — get an email when it moves on news →Email me when PRME moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to PRME's baseline. Nothing else.
Recent PRME events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease | Press release | GlobeNewswire | -2.50% | +7.00% | |
| Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency | Press release | GlobeNewswire | -7.92% | -14.96% | |
| Prime Medicine to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -1.08% | +0.27% | |
| Form 10-Q Prime Medicine, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.98% | -3.60% | |
| Form 8-K Prime Medicine, Inc. For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +0.98% | -3.60% | |
| Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates | Press release | GlobeNewswire | +0.98% | -3.60% | |
| Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease | Press release | GlobeNewswire | -1.99% | -1.67% | |
| Form 8-K Prime Medicine, Inc. For: Jul 06 | SEC filing · Form 8-K | SEC EDGAR | +5.58% | +7.44% | |
| Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics | Press release | GlobeNewswire | +5.58% | +7.44% | |
| Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD) | Press release | GlobeNewswire | +3.00% | +1.20% | |
| Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease | Press release | GlobeNewswire | +1.22% | -1.22% | |
| Form 8-K Prime Medicine, Inc. For: Jun 05 | SEC filing · Form 8-K | SEC EDGAR | +1.50% | -3.68% | |
| Prime Medicine to Present at Goldman Sachs 47th Annual Global Healthcare Conference | Press release | GlobeNewswire | -4.59% | -3.98% | |
| Prime Medicine to Present at Jefferies Global Healthcare Conference | Press release | GlobeNewswire | +0.31% | +4.62% | |
| Form 10-Q Prime Medicine, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +2.35% | -8.65% | |
| Form 8-K Prime Medicine, Inc. For: May 07 | SEC filing · Form 8-K | SEC EDGAR | +2.35% | -8.65% | |
| Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates | Press release | GlobeNewswire | +2.35% | -8.65% | |
| Form ARS Prime Medicine, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.50% | -3.27% | |
| Form DEF 14A Prime Medicine, Inc. For: Dec 31 | SEC filing · Form DEF | SEC EDGAR | +0.50% | -3.27% | |
| Form DEFA14A Prime Medicine, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +0.50% | -3.27% | |
| Form 8-K Prime Medicine, Inc. For: Apr 07 | SEC filing · Form 8-K | SEC EDGAR | -1.85% | -3.17% | |
| Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer | Press release | GlobeNewswire | +0.06% | +1.38% | |
| Form EFFECT Prime Medicine, Inc. | SEC filing · Form EFFECT | SEC EDGAR | -1.76% | -1.26% | |
| Form 10-K Prime Medicine, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.90% | -5.16% | |
| Form 8-K Prime Medicine, Inc. For: Mar 03 | SEC filing · Form 8-K | SEC EDGAR | -0.90% | -5.16% | |
| Form POS AM Prime Medicine, Inc. | SEC filing · Form POS | SEC EDGAR | -0.90% | -5.16% | |
| Form POSASR Prime Medicine, Inc. | SEC filing · Form POSASR | SEC EDGAR | -0.90% | -5.16% | |
| Form S-8 Prime Medicine, Inc. | SEC filing · Form S-8 | SEC EDGAR | -0.90% | -5.16% | |
| Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates | Press release | GlobeNewswire | -0.90% | -5.16% | |
| Prime Medicine to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +2.06% | +6.44% | |
| Form 8-K Prime Medicine, Inc. For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | +1.07% | +5.42% | |
| Prime Medicine to Present at 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | +6.07% | +6.60% | |
| Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease | Press release | GlobeNewswire | +2.64% | +5.78% | |
| Prime Medicine to Present at 8th Annual Evercore Healthcare Conference | Press release | GlobeNewswire | -0.80% | -1.33% | |
| Prime Medicine to Present at Jefferies Global Healthcare Conference | Press release | GlobeNewswire | -0.14% | +12.00% | |
| CORRECTION - Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates | Press release | GlobeNewswire | +1.17% | -0.91% | |
| Form 10-Q Prime Medicine, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.50% | -4.75% | |
| Form 8-K Prime Medicine, Inc. For: Nov 07 | SEC filing · Form 8-K | SEC EDGAR | -1.50% | -4.75% | |
| Form S-3ASR Prime Medicine, Inc. | SEC filing · Form S-3ASR | SEC EDGAR | -1.50% | -4.75% | |
| Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates | Press release | GlobeNewswire | -1.50% | -4.75% | |
| Prime Medicine Appoints Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer | Press release | GlobeNewswire | +0.20% | -6.75% | |
| Prime Medicine to Host Virtual KOL Event to Showcase Wilson’s Disease Strategy | Press release | GlobeNewswire | -0.23% | +13.04% | |
| Prime Medicine to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -1.73% | -3.45% | |
| Form 8-K Prime Medicine, Inc. For: Sep 08 | SEC filing · Form 8-K | SEC EDGAR | +2.24% | +2.37% | |
| Prime Medicine to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.57% | +3.13% | |
| Form 10-Q Prime Medicine, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.11% | -8.91% | |
| Form 8-K Prime Medicine, Inc. For: Aug 07 | SEC filing · Form 8-K | SEC EDGAR | +1.11% | -8.91% | |
| Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates | Press release | GlobeNewswire | +1.11% | -8.91% | |
| Form 8-K Prime Medicine, Inc. For: Aug 01 | SEC filing · Form 8-K | SEC EDGAR | -0.47% | -5.35% | |
| Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares | Press release | GlobeNewswire | -0.23% | +3.45% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the PRME section they belong to.
Where else PRME is measured.
PRME earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Prime Medicine, Inc.'s median reaction calculated?
Every labeled PRME news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 236 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 50% of PRME's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does PRME's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.